ST. LOUIS, Oct. 4 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a collaboration with the Institute of Research in Immunology and Cancer (IRIC) of the Universite de Montreal. This collaboration, made possible through grants from Genome Quebec and contributions by Sigma-Aldrich, will leverage Sigma's RNA Interference (RNAi) technologies for the purpose of identifying potential new drug targets.
Sigma-Aldrich and the Universite de Montreal have signed an agreement whereby the Institute's High Throughput Screening facility gains access to Sigma-Aldrich's RNAi intellectual property portfolio and its MISSION(R) shRNA library collection for both human and mouse genomes. This agreement marks the latest of a number of licensing and research collaborations the company has made as an ongoing commitment to bring cutting-edge technologies to researchers worldwide. By adopting the MISSION(R) shRNA library as their platform for RNAi screening, The University of Montreal will be utilizing the collective expertise of The RNAi Consortium (TRC), which consists of a partnership among the Broad Institute, MIT, Harvard, Dana Farber, Sigma- Aldrich as well as other research organizations and major pharmaceutical companies. In exchange, Sigma-Aldrich plans to utilize feedback from the collaboration to further its understanding of specific target function and to continue the development of tools for high throughput drug discovery.
"We are eager to work with the Universite de Montreal to provide
researchers access to the Sigma-Aldrich MISSION(R) RNAi portfolio of
products and intellectual property," said David Smoller, Ph.D., President
of Sigma- Aldrich's Research Biotechnology business unit. "RNAi is becoming
the leading technology used by researchers for the advancement of drug
discovery, commitment to this technology by the University and the
investment of Canadian government positions the facility to be a leader in
Copyright©2007 PR Newswire.
All rights reserved